Back to top
more

Palatin Technologies (PTN)

(Delayed Data from AMEX)

$1.82 USD

1.82
118,925

+0.10 (5.81%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.82 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Palatin (PTN) Begins Phase III Study For Dry Eye Disease

by Zacks Equity Research

Palatin (PTN) commences the pivotal phase III study evaluating PL9643 for the treatment of dry eye disease. Top-line data from the same is expected in the second half of 2022.

Here's Why Palatin Technologies, Inc. (PTN) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Palatin Technologies, Inc. (PTN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

New Strong Sell Stocks for March 11th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Palatin Technologies, Inc. (PTN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of -100.00% and -182.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Palatin (PTN) Jumps: Stock Rises 8.7%

by Zacks Equity Research

Palatin (PTN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Palatin (PTN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Vyleesi sales are likely to be in focus when Palatin (PTN) releases results for the second quarter of fiscal 2021.

Has Palatin Technologies (PTN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (PTN) Outperforming Other Medical Stocks This Year?

Palatin Technologies (PTN) Surges: Stock Moves 8% Higher

by Zacks Equity Research

Palatin Technologies (PTN) saw a big move last session, as its shares jumped 8% on the day, amid huge volumes.

Palatin's (PTN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on pipeline updates, when Palatin (PTN) releases fourth-quarter fiscal 2019 results.

Palatin (PTN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Palatin (PTN) closed at $0.91, marking a -1.7% move from the previous day.

Is Palatin Technologies (PTN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (PTN) Outperforming Other Medical Stocks This Year?

Palatin (PTN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Palatin (PTN) closed at $0.93 in the latest trading session, marking a -1.74% move from the prior day.

Palatin (PTN) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Palatin (PTN) closed the most recent trading day at $1, moving +0.37% from the previous trading session.

Is Palatin Technologies (PTN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (PTN) Outperforming Other Medical Stocks This Year?

Palatin Technologies (PTN) in Focus: Stock Moves 5.7% Higher

by Zacks Equity Research

Palatin Technologies (PTN) shares rose nearly 6% in the last trading session, amid huge volumes.

Earnings Preview: Palatin (PTN) Q1 Earnings Expected to Decline

by Zacks Equity Research

Palatin (PTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Palatin Technologies (PTN) in Focus: Stock Moves 13.2% Higher

by Zacks Equity Research

Palatin Technologies (PTN) was a big mover last session, as the company saw its shares rise more than 13% on the day.

    AMAG Pharma (AMAG) Incurs Loss in Q1, Revenues Rise Y/Y

    by Zacks Equity Research

    AMAG Pharmaceuticals, Inc. (AMAG) reported adjusted earnings of 99 cents per share in the first quarter of 2017 compared with earnings of 68 cents in the year-ago quarter

      Dicerna Pharmaceuticals (DRNA) Rises: Stock Climbs 14%

      by Zacks Equity Research

      Dicerna Pharmaceuticals, Inc. (DRNA) shares rose over 14% in the last trading session.

        AMAG Pharma (AMAG) Incurs Loss in Q4, Revenues Lag Estimates

        by Zacks Equity Research

        AMAG Pharmaceuticals, Inc. (AMAG) reported adjusted earnings of $1.36 per share in the fourth quarter of 2016, up from $1.04 in the year ago quarter.

          Indradip Ghosh headshot

          Palatin (PTN) Sees Hammer Chart Pattern: Time to Buy?

          by Indradip Ghosh

          Palatin Technologies, Inc. (PTN) has been struggling lately, but the selling pressure may be coming to an end soon.

            AMAG, Palatin Ink Deal to Focus on Female Sexual Disorder

            by Zacks Equity Research

            AMAG (AMAG) announced that it has entered into an agreement with Palatin (PTN) for the exclusive U.S. rights to develop and commercialize Rekynda.